NASDAQ:ADXS Advaxis Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Advaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.31 million shsAverage Volume607,996 shsMarket Capitalization$9.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Advaxis MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.33 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Advaxis. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for ADXS. Previous Next 0.0 Dividend Strength Dividend YieldAdvaxis does not currently pay a dividend.Dividend GrowthAdvaxis does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADXS. Previous Next 1.7 News and Social Media Coverage News SentimentAdvaxis has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Advaxis this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ADXS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Advaxis to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Advaxis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.30% of the stock of Advaxis is held by insiders.Percentage Held by InstitutionsOnly 0.06% of the stock of Advaxis is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Advaxis is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Advaxis is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address About Advaxis (NASDAQ:ADXS) StockAdvaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.Read More ADXS Stock News HeadlinesJune 29, 2022 | tmcnet.comAdvaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate CancerJune 27, 2022 | americanbankingnews.comAdvaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.comJune 9, 2022 | americanbankingnews.comAdvaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXS CUSIPN/A CIK1100397 Webwww.advaxis.com Phone609 452 9813Fax609-452-9818EmployeesN/AYear FoundedN/ACompany Calendar Today7/03/2022Fiscal Year End10/31/2022Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17.86 million Net MarginsN/A Pretax Margin-873.85% Return on Equity-42.66% Return on Assets-36.09% Debt Debt-to-Equity RatioN/A Current Ratio11.59 Quick Ratio11.59 Sales & Book Value Annual Sales$3.24 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / BookN/AMiscellaneous Outstanding Shares145,638,000Free Float145,201,000Market Cap$9.03 million OptionableNot Optionable Beta2.15 Advaxis Frequently Asked Questions Who are Advaxis' key executives? Advaxis' management team includes the following people: Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 58, Pay $625.4k)Mr. Igor Gitelman CPA, CPA, M.B.A., MBA, Chief Accounting Officer, Interim CFO & VP of Fin. (Age 46, Pay $297.87k)Dr. Andres A. Gutierrez M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 61, Pay $472.03k) Who are some of Advaxis' key competitors? Some companies that are related to Advaxis include NeuroSense Therapeutics (NRSN), ASLAN Pharmaceuticals (ASLN), Ceapro (CRPOF), Synaptogenix (SNPX), Galera Therapeutics (GRTX), BioVie (BIVI), Biofrontera (BFRI), Eledon Pharmaceuticals (ELDN), Angion Biomedica (ANGN), Oncorus (ONCR), Context Therapeutics (CNTX), Acura Pharmaceuticals (ACUR), NeuBase Therapeutics (NBSE), NuCana (NCNA) and Corbus Pharmaceuticals (CRBP). View all of ADXS's competitors. What other stocks do shareholders of Advaxis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), VistaGen Therapeutics (VTGN), Novavax (NVAX), (CELG), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX). What is Advaxis' stock symbol? Advaxis trades on the NASDAQ under the ticker symbol "ADXS." How do I buy shares of Advaxis? Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Advaxis make? Advaxis (NASDAQ:ADXS) has a market capitalization of $0.00 and generates $3.24 million in revenue each year. The company earns $-17.86 million in net income (profit) each year or ($0.10) on an earnings per share basis. How can I contact Advaxis? Advaxis' mailing address is 9 DEER PARK DRIVE SUITE K-1, MONMOUTH JUNCTION NJ, 08852. The official website for Advaxis is www.advaxis.com. The company can be reached via phone at 609 452 9813, via email at ir@advaxis.com, or via fax at 609-452-9818. This page (NASDAQ:ADXS) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here